Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial health with nearly $1 billion in available capital, an optimistic outlook on revenue and EPS growth, and strategic acquisitions like XOMA expected to drive synergies and EPS accretion. Despite a GAAP EPS loss, the adjusted metrics and guidance remain robust, with promising pipeline developments and a stable royalty growth trajectory. The Q&A session reinforced confidence in sustained growth without the need for additional deals, and management's clear responses indicate a well-managed strategy. Considering the small-cap nature of the stock, a positive reaction is likely.
Key Financial Performance
Royalty Revenue $43 million, increasing 56% year-over-year. The growth was driven primarily by continued growth from Filspari, Ohtuvayre, and Qarziba.
Total Revenue $52 million, up 14% year-over-year. This reflects strong underlying momentum in the business.
Adjusted EPS $1.63, up 23% year-over-year. This reflects strong operating leverage and higher royalty contributions.
R&D Expense $2.1 million in the quarter compared to $50.1 million in the prior year period. The prior year included a one-time $44 million accounting charge related to Castle Creek's funding of the Phase III D-Fi study.
G&A Expense $21 million compared with $19 million in the prior year, reflecting higher employee-related costs as the business development function scales.
Nonoperating Expense $41.6 million compared to $14 million in the prior year period, primarily driven by changes in the fair value of investments in Pelthos and other equity holdings.
GAAP Diluted EPS Loss of $0.67 in the first quarter compared to a loss of $2.21 in the prior year period. The 2026 loss was driven by fair value adjustments on equity holdings, while the prior year loss reflected a one-time $44 million accounting charge.
Cash and Investments Approximately $780 million at the end of the quarter, along with $200 million of undrawn capacity under the revolving credit facility, giving nearly $1 billion of available capital.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Filspari: FDA approval for FSGS, marking it as the first and only approved medicine for this condition. Expansion beyond IgA nephropathy into a second rare kidney disease. Significant growth expected.
QTORIN rapamycin: Positive Phase III results for MLMs, with potential to become the first FDA-approved therapy for this condition. Estimated U.S. commercial opportunity of $1 billion to $3 billion annually across MLM and CVM indications.
XOMA Royalty Acquisition: Acquisition of XOMA Royalty Corporation, adding over 120 commercial, clinical, and preclinical stage assets. Expected to be immediately accretive and accelerate long-term growth.
Geographic Expansion: Filspari's expansion into Japan and China for IgAN and Ohtuvayre, respectively, expected to drive growth.
Royalty Aggregation Model: Shifted to a pure royalty aggregation model in 2022, reducing operating expenses from $90 million to $40 million and increasing profitability.
Portfolio Growth: Expanded from 7 to 15 commercial assets and closed 18 deals in 3 years, adding high-potential assets to the late-stage clinical pipeline.
Strategic Shift in 2022: Transitioned from infrastructure-heavy technology platforms to a royalty aggregation model, improving operating leverage and profitability.
XOMA Royalty Integration: Integration of XOMA portfolio expected to create significant operational and financial synergies, enhancing Ligand's position as a biopharma royalty aggregator.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces regulatory risks associated with the approval and commercialization of its products, such as the need for FDA approvals for new drugs and therapies, including QTORIN rapamycin and Filspari. Delays or failures in obtaining these approvals could impact revenue and growth.
Market Competition: The company operates in highly competitive markets, particularly in areas like IgAN and FSGS, where new therapies are entering the market. This could impact the market share and revenue potential of products like Filspari.
Integration Risks: The acquisition of XOMA Royalty Corporation involves significant integration efforts. Failure to achieve operational and financial synergies as anticipated could adversely affect the company's performance.
Supply Chain and Operational Risks: The company relies on partners and external entities for the commercialization and distribution of its products. Any disruptions in these partnerships or supply chains could negatively impact operations.
Litigation Risks: The company is exposed to litigation risks, such as the ongoing litigation with Janssen associated with the XOMA acquisition. While Ligand has no obligation to fund the litigation, the outcome could still impact financials.
Economic and Financial Risks: The company’s financial performance is subject to economic uncertainties, including changes in reimbursement policies, tax regulations, and market conditions that could affect cash flow and profitability.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
EPS Guidance for 2026 and 2027: Ligand projects adjusted EPS for 2026 to be in the range of $8.50 to $9.50. The acquisition of XOMA Royalty is expected to add $0.50 per share of adjusted EPS in 2026 and $1.50 in 2027.
Revenue Guidance for 2026: Total revenue is expected to be between $270 million and $310 million, with royalty revenue projected at $225 million to $250 million.
Capital Deployment Strategy: Ligand plans to invest $150 million to $250 million annually in new royalty opportunities, supported by a projected operating cash flow of approximately $300 million in 2027.
XOMA Royalty Acquisition Impact: The acquisition is expected to be immediately accretive, adding over 120 assets to Ligand's portfolio, including seven marketed products and nearly doubling the Phase II and Phase III assets. This acquisition is anticipated to strengthen Ligand's position as a biopharma royalty aggregator and create significant operational and financial synergies.
Filspari Growth Projections: Filspari, now the largest commercial royalty asset, is expected to drive significant growth with its expansion into FSGS. Travere has guided to a $3 billion peak opportunity across IgAN and FSGS, translating into a potential $270 million annual royalty to Ligand.
QTORIN Rapamycin Commercial Potential: Palvella projects a U.S. commercial opportunity of $1 billion to $3 billion annually for QTORIN rapamycin across MLM and CVM indications, translating into a potential $100 million to $300 million peak annual royalty revenue to Ligand.
Pipeline and Portfolio Expansion: Ligand anticipates continued growth through its robust pipeline, including eight key programs and the integration of XOMA's assets. Key catalysts include regulatory submissions and approvals for Filspari, QTORIN rapamycin, and other late-stage assets.
Long-Term Growth and Royalty Revenue: Ligand expects to achieve predictable compounding royalty revenue growth through its expanded portfolio, with long-dated royalty cash flows extending past 2040.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you explain how the XOMA deal came to pass and why it makes sense now?
A:The XOMA deal was a result of a long-standing relationship with the XOMA team. Discussions began in December, with terms and structure aligned in April. The deal provides XOMA shareholders with liquidity and attractive returns, while Ligand benefits from portfolio synergies, accelerated growth, and immediate EPS accretion.
Q:Are there others in the pipeline similar to XOMA, or do you expect to revert back to individual drug investments?
A:The majority of the pipeline consists of single or double assets. The XOMA portfolio is unique in its breadth, and while there are other larger deals involving multiple assets, they are not as broad as XOMA.
Q:To what extent does the earlier-stage portfolio impact your commitment to conducting 4-5 deal targets per year?
A:Ligand does not need additional deals to sustain over 20% growth for the next 5 years due to the growth embedded in the current portfolio. However, the company plans to continue adding new deals and assets to compound growth further.
Q:Could you elaborate on the key performance indicators or specific achievements that might lead to an upward revision of Filspari's projected contribution for the remainder of the year?
A:Filspari's contribution for the year remains unchanged due to its approval timeline shifting by a quarter. The $0.50 increase in guidance is related to the XOMA acquisition, with significant impact from FSGS sales expected in 2028 and beyond.
Q:What is the strategic thinking behind the TR Beta program termination of Viking, and how are the 2809 and 0214 assets being carried on the books?
A:Ligand aims to move the 2809 asset forward in development due to its high potential in the MASH market. The assets are not carried on the balance sheet as intangible assets have been fully amortized. Financial impact is minimal, with only minor legal expenses expected.
Q:How does the recent label expansion for Tzield change your view on the size of the opportunity, and how might that translate into royalties for Ligand?
A:The label expansion is seen as an incremental addition to Tzield sales. Identifying eligible patients requires significant investment, and while the expansion is encouraging, it is not expected to cause a meaningful shift in peak sales potential.
Q:What gives you confidence in achieving the full-year Captisol guidance, and how should we think about the pacing of contract revenue for the remainder of the year?
A:Ligand has visibility to Captisol orders into early 2027 and expects to meet the $35-$40 million guidance range. Contract revenue is lumpy due to regulatory and commercial milestones, but the company is confident in meeting its guidance range.
Q:Can you comment on the ease of integrating XOMA post-closing, expected synergies, and impact on near-term deal activity?
A:The XOMA integration is expected to have high synergies, approaching 100%. Ligand is scaling its team and has sufficient cash flow to maintain its deal pace without immediate financing. The integration will not significantly impact near-term deal activity.
Q:Will Ligand take on the responsibility of out-licensing XOMA's acquired assets, and is this a potential strategy for Ligand's current assets?
A:Ligand plans to manage and potentially out-license XOMA's assets as part of its portfolio management strategy. The company is also open to repartnering its own assets if needed, as demonstrated by the lasofoxifene example.
Q:Do you anticipate any milestones from XOMA in the second half of the year, 2026?
A:Yes, Ligand expects to realize some milestones from the XOMA portfolio in the second half of 2026, assuming the acquisition closes as expected in the third quarter.
Q:How quickly will Ligand be able to use XOMA's R&D assets and NOLs, and will there be any restrictions due to M&A?
A:Ligand will be able to use XOMA's Section 174 R&D tax credits immediately, which will provide significant tax efficiency. The NOLs will be limited, but the overall tax benefits are expected to be substantial.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses provided sufficient detail and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CVM
CVR
FSGS patient
IgAN FSGS
Ligand portfolio
MLM
Mirum
NDA
OJEMDA
Ohtuvayre Qarziba
PSC
Phase II
Phase III
accounting charge
acquisition Royalty
approval FSGS
asset potential
cash flow
catalyst
cholangitis
compounding
employee
endpoint
estimate patient
expense period
field
litigation
medicine
outlook royalty
overlap IgAN
point royalty
portfolio expansion
portfolio term
proceeds
professional overlap
rapamycin
royalty aggregation
tax
LGND Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript
Positive5-9
The earnings call highlights strong financial health with nearly $1 billion in available capital, an optimistic outlook on revenue and EPS growth, and strategic acquisitions like XOMA expected to drive synergies and EPS accretion. Despite a GAAP EPS loss, the adjusted metrics and guidance remain robust, with promising pipeline developments and a stable royalty growth trajectory. The Q&A session reinforced confidence in sustained growth without the need for additional deals, and management's clear responses indicate a well-managed strategy. Considering the small-cap nature of the stock, a positive reaction is likely.
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call indicates strong financial performance, with raised guidance and record high revenues. Product development shows momentum with potential blockbuster drugs and a robust pipeline. Market strategy is solid with royalty revenue growth and strategic investments. Financial health is stable with manageable expenses and significant cash reserves. Shareholder returns are likely supported by positive financial outcomes. Q&A insights reinforce optimistic guidance and strategic focus. Given the market cap, the stock price is expected to react positively, likely increasing by 2% to 8% over the next two weeks.
Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript
Positive11-8
The earnings call summary highlights strong financial performance with significant revenue and EPS growth, positive product launches, and raised guidance. The Q&A session reveals management's focus on strategic investments and alignment with FDA initiatives, which are viewed positively by analysts. Despite competitive risks, the company's cash position and strategic investments provide a solid foundation. The raised guidance and strong product performance contribute to a positive outlook, suggesting a stock price increase of 2% to 8% over the next two weeks.
Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
Positive8-7
The earnings call highlights strong financial performance with improved GAAP and non-GAAP net income. Management's optimistic outlook on product launches and strategic partnerships, like with Merck, along with robust M&A opportunities, indicate strong growth potential. Although there are concerns about operating expenses and tax rates, the overall sentiment is positive, especially with expected revenue growth and strategic investments. The market cap suggests moderate reaction, leading to a positive stock price movement prediction.
LGND Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
